Formosa Pharmaceuticals
is a preclinical and clinical stage biopharmaceutical company with focus in the therapeutic areas of ophthalmology, oncology, and anti-infectives.
Formosa Pharma is developing a unique pipeline consisting of risk-diverse development modes, including 505(b)(2), biosimilars, and NCEs. Our proprietary APNT nanoparticle formulation platform, from which lead program APP13007 is derived, is available for application to drug candidates in need of improving pharmacokinetics and bioavailability.
